Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?

Leonardo Roever1, Giuseppe Biondi-Zoccai2, Sunil V Rao3

  • 1Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil.

Clinical Therapeutics
|February 14, 2017
PubMed

Insights

Lifestyle changes and combination therapy effectively reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. These interventions are crucial for preventing atherosclerosis and achieving lipid targets in high-risk patients.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Metabolic Disorders

Background:

  • Cardiovascular disease (CVD) is the primary global cause of mortality.
  • Dyslipidemia, characterized by elevated low-density lipoprotein cholesterol (LDL-C), drives atherosclerosis development.
  • Managing dyslipidemia is key for cardiovascular event prevention.

Purpose of the Study:

  • To evaluate the efficacy of therapeutic lifestyle changes and combination therapy in managing dyslipidemia.
  • To assess the impact of interventions on reducing cardiovascular risk.
  • To determine if LDL-C targets can be achieved in high-risk populations.

Main Methods:

  • Review of therapeutic lifestyle changes including diet, exercise, and weight management.
  • Analysis of combination therapy's effect on LDL-C levels.
  • Assessment of cardiovascular risk reduction in primary and secondary prevention.

Main Results:

  • Therapeutic lifestyle changes significantly reduce cardiovascular risk.
  • Combination therapy demonstrated effectiveness in lowering LDL-C.
  • Achieved target LDL-C levels in patients with high cardiovascular risk.

Conclusions:

  • Lifestyle modifications are fundamental for cardiovascular risk reduction.
  • Combination therapy offers a potent strategy for managing dyslipidemia.
  • Interventions are effective in achieving therapeutic goals for high-risk individuals.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
797
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320